pubmed-article:6529530 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:6529530 | lifeskim:mentions | umls-concept:C2349001 | lld:lifeskim |
pubmed-article:6529530 | lifeskim:mentions | umls-concept:C0681850 | lld:lifeskim |
pubmed-article:6529530 | lifeskim:mentions | umls-concept:C1706203 | lld:lifeskim |
pubmed-article:6529530 | lifeskim:mentions | umls-concept:C2697811 | lld:lifeskim |
pubmed-article:6529530 | lifeskim:mentions | umls-concept:C0015695 | lld:lifeskim |
pubmed-article:6529530 | lifeskim:mentions | umls-concept:C0683140 | lld:lifeskim |
pubmed-article:6529530 | lifeskim:mentions | umls-concept:C1550501 | lld:lifeskim |
pubmed-article:6529530 | pubmed:issue | 6 | lld:pubmed |
pubmed-article:6529530 | pubmed:dateCreated | 1985-5-10 | lld:pubmed |
pubmed-article:6529530 | pubmed:abstractText | The effect of fatty degeneration of liver parenchyma on drug metabolism was investigated in 21 obese non-insulin-dependent diabetic subjects by measuring plasma antipyrine kinetics, hepatic cytochrome P-450, liver size and the extent of fatty infiltration. The hepatic drug metabolising capacity, as measured by total antipyrine clearance and the estimated total amount of cytochrome P-450, was at the same level as in non-diabetic control subjects with normal livers. Relative antipyrine clearance (per unit weight of liver) and cytochrome P-450 concentrations were significantly lower in the diabetics than in controls. The extent of fatty infiltration correlated poorly with the indices of drug metabolism. In non-insulin-dependent diabetics, slight to moderate hepatic fatty infiltration, without more serious structural distortion interfering with hepatic blood flow or hepatocellular function, seems to have only a minor influence on drug metabolism. | lld:pubmed |
pubmed-article:6529530 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6529530 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6529530 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6529530 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6529530 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6529530 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6529530 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6529530 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6529530 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6529530 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6529530 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6529530 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6529530 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6529530 | pubmed:language | eng | lld:pubmed |
pubmed-article:6529530 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6529530 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:6529530 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6529530 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6529530 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6529530 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:6529530 | pubmed:month | Dec | lld:pubmed |
pubmed-article:6529530 | pubmed:issn | 0306-5251 | lld:pubmed |
pubmed-article:6529530 | pubmed:author | pubmed-author:PelkonenR ORO | lld:pubmed |
pubmed-article:6529530 | pubmed:author | pubmed-author:SotaniemiE... | lld:pubmed |
pubmed-article:6529530 | pubmed:author | pubmed-author:LuomaP VPV | lld:pubmed |
pubmed-article:6529530 | pubmed:author | pubmed-author:PitkänenUU | lld:pubmed |
pubmed-article:6529530 | pubmed:author | pubmed-author:PirttiahoH... | lld:pubmed |
pubmed-article:6529530 | pubmed:author | pubmed-author:SalmelaP IPI | lld:pubmed |
pubmed-article:6529530 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:6529530 | pubmed:volume | 18 | lld:pubmed |
pubmed-article:6529530 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:6529530 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:6529530 | pubmed:pagination | 895-9 | lld:pubmed |
pubmed-article:6529530 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
pubmed-article:6529530 | pubmed:meshHeading | pubmed-meshheading:6529530-... | lld:pubmed |
pubmed-article:6529530 | pubmed:meshHeading | pubmed-meshheading:6529530-... | lld:pubmed |
pubmed-article:6529530 | pubmed:meshHeading | pubmed-meshheading:6529530-... | lld:pubmed |
pubmed-article:6529530 | pubmed:meshHeading | pubmed-meshheading:6529530-... | lld:pubmed |
pubmed-article:6529530 | pubmed:meshHeading | pubmed-meshheading:6529530-... | lld:pubmed |
pubmed-article:6529530 | pubmed:meshHeading | pubmed-meshheading:6529530-... | lld:pubmed |
pubmed-article:6529530 | pubmed:meshHeading | pubmed-meshheading:6529530-... | lld:pubmed |
pubmed-article:6529530 | pubmed:meshHeading | pubmed-meshheading:6529530-... | lld:pubmed |
pubmed-article:6529530 | pubmed:meshHeading | pubmed-meshheading:6529530-... | lld:pubmed |
pubmed-article:6529530 | pubmed:meshHeading | pubmed-meshheading:6529530-... | lld:pubmed |
pubmed-article:6529530 | pubmed:meshHeading | pubmed-meshheading:6529530-... | lld:pubmed |
pubmed-article:6529530 | pubmed:meshHeading | pubmed-meshheading:6529530-... | lld:pubmed |
pubmed-article:6529530 | pubmed:meshHeading | pubmed-meshheading:6529530-... | lld:pubmed |
pubmed-article:6529530 | pubmed:year | 1984 | lld:pubmed |
pubmed-article:6529530 | pubmed:articleTitle | Drug metabolism in diabetic subjects with fatty livers. | lld:pubmed |
pubmed-article:6529530 | pubmed:publicationType | Journal Article | lld:pubmed |